Monday, March 12, 2012

Is AstraZeneca's Brennan on the way out?


One top-five AstraZeneca shareholder said Brennan remained "very tarnished" by the 2007 U.S. biotechnology deal, which was slammed at the time and has been criticised ever since for the high price paid and the scant pipeline rewards it yielded.

Given that poor track record, some investors have questioned whether Brennan, who has been in the top job for six years, will continue to lead the company - especially now that an new chairman has been found, offering scope for change.

Posted via email from Jack's posterous

No comments: